Cargando…

Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study

Objectives To test whether bisphosphonate use is related to improved implant survival after total arthroplasty of the knee or hip. Design Population based retrospective cohort study. Setting Primary care data from the United Kingdom. Participants All patients undergoing primary total arthroplasty of...

Descripción completa

Detalles Bibliográficos
Autores principales: Prieto-Alhambra, Daniel, Javaid, M Kassim, Judge, Andrew, Murray, David, Carr, Andy, Cooper, Cyrus, Arden, Nigel K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232250/
https://www.ncbi.nlm.nih.gov/pubmed/22147909
http://dx.doi.org/10.1136/bmj.d7222
_version_ 1782218344249688064
author Prieto-Alhambra, Daniel
Javaid, M Kassim
Judge, Andrew
Murray, David
Carr, Andy
Cooper, Cyrus
Arden, Nigel K
author_facet Prieto-Alhambra, Daniel
Javaid, M Kassim
Judge, Andrew
Murray, David
Carr, Andy
Cooper, Cyrus
Arden, Nigel K
author_sort Prieto-Alhambra, Daniel
collection PubMed
description Objectives To test whether bisphosphonate use is related to improved implant survival after total arthroplasty of the knee or hip. Design Population based retrospective cohort study. Setting Primary care data from the United Kingdom. Participants All patients undergoing primary total arthroplasty of the knee (n=18 726) or hip (n=23 269) in 1986-2006 within the United Kingdom’s General Practice Research Database. We excluded patients with a history of hip fracture before surgery or rheumatoid arthritis, and individuals younger than 40 years at surgery. Intervention Bisphosphonate users were classified as patients with at least six prescriptions of bisphosphonates or at least six months of prescribed bisphosphonate treatment with more than 80% adherence before revision surgery. Outcome measures Revision arthroplasties occurring after surgery, identified by READ and OXMIS codes. Parametric survival models were used to determine effects on implant survival with propensity score adjustment to account for confounding by indication. Results Of 41 995 patients undergoing primary hip or knee arthroplasty, we identified 1912 bisphosphonate users, who had a lower rate of revision at five years than non-users (0.93% (95% confidence interval 0.52% to 1.68%) v 1.96% (1.80% to 2.14%)). Implant survival was significantly longer in bisphosphonate users than in non-users in propensity adjusted models (hazard ratio 0.54 (0.29 to 0.99); P=0.047) and had an almost twofold increase in time to revision after hip or knee arthroplasty (time ratio 1.96 (1.01 to 3.82)). Assuming 2% failure over five years, we estimated that the number to treat to avoid one revision was 107 for oral bisphosphonates. Conclusions In patients undergoing lower limb arthroplasty, bisphosphonate use was associated with an almost twofold increase in implant survival time. These findings require replication and testing in experimental studies for confirmation.
format Online
Article
Text
id pubmed-3232250
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-32322502011-12-07 Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study Prieto-Alhambra, Daniel Javaid, M Kassim Judge, Andrew Murray, David Carr, Andy Cooper, Cyrus Arden, Nigel K BMJ Research Objectives To test whether bisphosphonate use is related to improved implant survival after total arthroplasty of the knee or hip. Design Population based retrospective cohort study. Setting Primary care data from the United Kingdom. Participants All patients undergoing primary total arthroplasty of the knee (n=18 726) or hip (n=23 269) in 1986-2006 within the United Kingdom’s General Practice Research Database. We excluded patients with a history of hip fracture before surgery or rheumatoid arthritis, and individuals younger than 40 years at surgery. Intervention Bisphosphonate users were classified as patients with at least six prescriptions of bisphosphonates or at least six months of prescribed bisphosphonate treatment with more than 80% adherence before revision surgery. Outcome measures Revision arthroplasties occurring after surgery, identified by READ and OXMIS codes. Parametric survival models were used to determine effects on implant survival with propensity score adjustment to account for confounding by indication. Results Of 41 995 patients undergoing primary hip or knee arthroplasty, we identified 1912 bisphosphonate users, who had a lower rate of revision at five years than non-users (0.93% (95% confidence interval 0.52% to 1.68%) v 1.96% (1.80% to 2.14%)). Implant survival was significantly longer in bisphosphonate users than in non-users in propensity adjusted models (hazard ratio 0.54 (0.29 to 0.99); P=0.047) and had an almost twofold increase in time to revision after hip or knee arthroplasty (time ratio 1.96 (1.01 to 3.82)). Assuming 2% failure over five years, we estimated that the number to treat to avoid one revision was 107 for oral bisphosphonates. Conclusions In patients undergoing lower limb arthroplasty, bisphosphonate use was associated with an almost twofold increase in implant survival time. These findings require replication and testing in experimental studies for confirmation. BMJ Publishing Group Ltd. 2011-12-06 /pmc/articles/PMC3232250/ /pubmed/22147909 http://dx.doi.org/10.1136/bmj.d7222 Text en © Prieto-Alhambra et al 2011 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Research
Prieto-Alhambra, Daniel
Javaid, M Kassim
Judge, Andrew
Murray, David
Carr, Andy
Cooper, Cyrus
Arden, Nigel K
Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study
title Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study
title_full Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study
title_fullStr Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study
title_full_unstemmed Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study
title_short Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study
title_sort association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232250/
https://www.ncbi.nlm.nih.gov/pubmed/22147909
http://dx.doi.org/10.1136/bmj.d7222
work_keys_str_mv AT prietoalhambradaniel associationbetweenbisphosphonateuseandimplantsurvivalafterprimarytotalarthroplastyofthekneeorhippopulationbasedretrospectivecohortstudy
AT javaidmkassim associationbetweenbisphosphonateuseandimplantsurvivalafterprimarytotalarthroplastyofthekneeorhippopulationbasedretrospectivecohortstudy
AT judgeandrew associationbetweenbisphosphonateuseandimplantsurvivalafterprimarytotalarthroplastyofthekneeorhippopulationbasedretrospectivecohortstudy
AT murraydavid associationbetweenbisphosphonateuseandimplantsurvivalafterprimarytotalarthroplastyofthekneeorhippopulationbasedretrospectivecohortstudy
AT carrandy associationbetweenbisphosphonateuseandimplantsurvivalafterprimarytotalarthroplastyofthekneeorhippopulationbasedretrospectivecohortstudy
AT coopercyrus associationbetweenbisphosphonateuseandimplantsurvivalafterprimarytotalarthroplastyofthekneeorhippopulationbasedretrospectivecohortstudy
AT ardennigelk associationbetweenbisphosphonateuseandimplantsurvivalafterprimarytotalarthroplastyofthekneeorhippopulationbasedretrospectivecohortstudy